

<b>Examiner-Initiated Interview Summary</b>	<b>Application No.</b>	<b>Applicant(s)</b>	
	10/683,576	VATNER ET AL.	
	<b>Examiner</b>	<b>Art Unit</b>	
	Robert B. Mondesi	1653	

**All Participants:**

 (1) Robert B. Mondesi.

 (2) Christine E. Dietzel.
**Status of Application:** Pending

(3) \_\_\_\_\_.

(4) \_\_\_\_\_.

**Date of Interview:** 5 May 2005
**Time:** 11:00 am
**Type of Interview:**

- ☒ Telephonic  
☐ Video Conference  
☐ Personal (Copy given to: ☐ Applicant ☐ Applicant's representative)

 Exhibit Shown or Demonstrated: ☐ Yes ☐ No

If Yes, provide a brief description:

**Part I.**

Rejection(s) discussed:

Claims discussed:

12

Prior art documents discussed:

**Part II.**

SUBSTANCE OF INTERVIEW DESCRIBING THE GENERAL NATURE OF WHAT WAS DISCUSSED:

**Part III.**

- ☐ It is not necessary for applicant to provide a separate record of the substance of the interview, since the interview directly resulted in the allowance of the application. The examiner will provide a written summary of the substance of the interview in the Notice of Allowability.  
☐ It is not necessary for applicant to provide a separate record of the substance of the interview, since the interview did not result in resolution of all issues. A brief summary by the examiner appears in Part II above.

(Examiner/SPE Signature)

(Applicant/Applicant's Representative Signature – if appropriate)

The examiner requested an election of species with regards to claim 12, compounds that used in combination with Mst1 inhibitors in the method of the invention. The applicant's representative responded by stating that such a requirement is not appropriate since all the compounds in claim 12 are known to be useful in treating cardiac disease and are not germane with respect to the modality of the invention. In response the examiner agreed and removed the requirement.